- Home
- EVV vs QURE Comparison
EVV vs QURE Comparison
Compare EVV & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVV | QURE |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2003 | 2013 |
Fundamental Metrics
Financial Performance| Metric | EVV | QURE |
|---|---|---|
| Price | $9.37 | $28.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | 363.8K | ★ 1.9M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $126.12 |
| Revenue Next Year | N/A | $200.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.97 | $8.73 |
| 52 Week High | $10.41 | $71.50 |
Technical Indicators
Market Signals| Indicator | EVV | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 66.41 |
| Support Level | $8.97 | $20.20 |
| Resistance Level | $9.59 | $29.03 |
| Average True Range (ATR) | 0.10 | 1.71 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 75.00 | 68.62 |
Price Performance
Historical ComparisonAbout EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.